[go: up one dir, main page]

WO1993001820A3 - Inhibition of non-cd4 mediated hiv infection - Google Patents

Inhibition of non-cd4 mediated hiv infection Download PDF

Info

Publication number
WO1993001820A3
WO1993001820A3 PCT/US1992/005985 US9205985W WO9301820A3 WO 1993001820 A3 WO1993001820 A3 WO 1993001820A3 US 9205985 W US9205985 W US 9205985W WO 9301820 A3 WO9301820 A3 WO 9301820A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv infection
inhibition
mediated hiv
hiv
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/005985
Other languages
French (fr)
Other versions
WO1993001820A2 (en
Inventor
Benson M Curtis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO1993001820A2 publication Critical patent/WO1993001820A2/en
Publication of WO1993001820A3 publication Critical patent/WO1993001820A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A specific nonCD4-gp120 receptor has been isolated which has specific binding affinity for the gp120 surface protein of human immunodeficiency virus (HIV). Methods of treating HIV infection of CD4 negative cells, such as colon and brain, are disclosed together with methods of detecting HIV and diagnostic kits.
PCT/US1992/005985 1991-07-16 1992-07-16 Inhibition of non-cd4 mediated hiv infection Ceased WO1993001820A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73121491A 1991-07-16 1991-07-16
US731,214 1991-07-16

Publications (2)

Publication Number Publication Date
WO1993001820A2 WO1993001820A2 (en) 1993-02-04
WO1993001820A3 true WO1993001820A3 (en) 1993-05-27

Family

ID=24938578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005985 Ceased WO1993001820A2 (en) 1991-07-16 1992-07-16 Inhibition of non-cd4 mediated hiv infection

Country Status (7)

Country Link
AU (1) AU2373792A (en)
IE (1) IE922308A1 (en)
IL (1) IL102508A0 (en)
MX (1) MX9204131A (en)
PT (1) PT100694A (en)
WO (1) WO1993001820A2 (en)
ZA (1) ZA925305B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748483B1 (en) * 1996-05-07 1998-07-24 Orstom MEANS FOR THE FIGHT OR DIAGNOSIS OF HIV INFECTION
WO1996041884A1 (en) * 1995-06-09 1996-12-27 Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) Means for detecting and preventing hiv infection involving use of receptors or binding sites capable of interacting with gp120
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
AUPQ278899A0 (en) * 1999-09-13 1999-10-07 Csl Limited Dendritic cell membrane protein cire
US7691591B2 (en) 2002-09-20 2010-04-06 Stichting Katholieke Universiteit Methods of identifying and isolating cells expressing DC-sign
WO2004026326A2 (en) 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
US20060134100A1 (en) 2002-11-05 2006-06-22 Ali Amara Dc-sign blockers and their use for preventing or treating viral infections
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
EP2241331A3 (en) 2003-12-15 2011-03-09 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
US20060105063A1 (en) * 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
GB0702183D0 (en) * 2007-02-05 2007-03-14 Iti Scotland Ltd Pathogen binding

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AIDS vol. 3, no. 12, 1989, pages 793 - 798 LARKIN. M. ET AL.; 'Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition"' cited in the application *
BULL. INST. PASTEUR vol. 89, no. 2, June 1991, IZRACHI, Y. ET AL.; 'Efficient binding , fusion and entry of HIV1 into CD4 negative neural cells : a mechanism for neuropathogenesis in Aids.' *
JOURNAL OF MEDICAL VIROLOGY vol. 35, no. 3, November 1991, pages 187 - 191 MORRISSON, N.K. ET AL.; 'Growth of human immunodeficiency virus 1 in cultured cells in the absence of the CD4 antigen."' *
NATURE. vol. 337, 1989, LONDON GB pages 368 - 370 CLAPHAM, P.R. ET AL.; 'Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.' cited in the application *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, September 1992, WASHINGTON US pages 8356 - 8360 Curtis, Benson M.; Scharnowske, S.; Watson, A.J.; 'Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.' *
THE JOURNAL OF EXPERIMENTAL MEDECINE vol. 169, January 1989, THE ROCKEFELLER UNIV. PRESS pages 185 - 196 EZEKOWITZ, R.A.B. ET AL.; 'A human serum mannose binding protein inhibits in vitro infection by the human immunodeficeincy virus.' *

Also Published As

Publication number Publication date
WO1993001820A2 (en) 1993-02-04
MX9204131A (en) 1993-04-01
IL102508A0 (en) 1993-01-14
IE922308A1 (en) 1993-01-27
ZA925305B (en) 1993-06-14
PT100694A (en) 1993-10-29
AU2373792A (en) 1993-02-23

Similar Documents

Publication Publication Date Title
WO1988009181A3 (en) Monoclonal antibodies neutralizing hiv-1
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
CA2107732A1 (en) Retrovirus from the hiv group and its use
WO1993001820A3 (en) Inhibition of non-cd4 mediated hiv infection
CA2143163A1 (en) Peptides derived from a retrovirus of the hiv group, and their use
EP1026263A3 (en) Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0891982A3 (en) HIV peptides
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
DK0479909T3 (en) Bispecific reagents for AIDS treatment
CA2363947A1 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
CA2082825A1 (en) Inhibition of viral infection
CA2169603A1 (en) Retrovirus from the hiv group and its use
WO1991015512A3 (en) Hiv envelope polypeptides
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU2567888A (en) Hiv peptides and methods for detection of hiv
AU7028998A (en) Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells
CA2131087A1 (en) Streptomyces strains and methods for selectively producing a single streptogramin component
AU7289587A (en) Immunosuppressive factor from human immunodeficiency virus (hiv) or hiv infected cells or cell lines, its use, corresponding antibodies and their use
EP0311108A3 (en) Anti-hiv active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside
EP0270114A3 (en) Env/gag polypeptides
AU5061090A (en) Aids therapy
AU2530795A (en) Assay for hiv-1 group o using at least one gp41 peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA